Specific Susceptibility to COVID-19 in Adults with Down Syndrome
Abstract The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer’s disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Neuromolecular medicine - 23(2021), 4 vom: 04. März, Seite 561-571 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Illouz, Tomer [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2021. corrected publication 2021 |
|---|
| doi: |
10.1007/s12017-021-08651-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2077521511 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2077521511 | ||
| 003 | DE-627 | ||
| 005 | 20230512141227.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12017-021-08651-5 |2 doi | |
| 035 | |a (DE-627)OLC2077521511 | ||
| 035 | |a (DE-He213)s12017-021-08651-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Illouz, Tomer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Specific Susceptibility to COVID-19 in Adults with Down Syndrome |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021. corrected publication 2021 | ||
| 520 | |a Abstract The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer’s disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Down syndrome | |
| 650 | 4 | |a Immune dysregulation | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine | |
| 700 | 1 | |a Biragyn, Arya |4 aut | |
| 700 | 1 | |a Frenkel-Morgenstern, Milana |4 aut | |
| 700 | 1 | |a Weissberg, Orly |4 aut | |
| 700 | 1 | |a Gorohovski, Alessandro |4 aut | |
| 700 | 1 | |a Merzon, Eugene |4 aut | |
| 700 | 1 | |a Green, Ilan |4 aut | |
| 700 | 1 | |a Iulita, Florencia |4 aut | |
| 700 | 1 | |a Flores-Aguilar, Lisi |4 aut | |
| 700 | 1 | |a Dierssen, Mara |4 aut | |
| 700 | 1 | |a De Toma, Ilario |4 aut | |
| 700 | 1 | |a Lifshitz, Hefziba |4 aut | |
| 700 | 1 | |a Antonarakis, Stylianos E. |4 aut | |
| 700 | 1 | |a Yu, Eugene |4 aut | |
| 700 | 1 | |a Herault, Yann |4 aut | |
| 700 | 1 | |a Potier, Marie-Claude |4 aut | |
| 700 | 1 | |a Botté, Alexandra |4 aut | |
| 700 | 1 | |a Roper, Randall |4 aut | |
| 700 | 1 | |a Sredni, Benjamin |4 aut | |
| 700 | 1 | |a Sarid, Ronit |4 aut | |
| 700 | 1 | |a London, Jacqueline |4 aut | |
| 700 | 1 | |a Mobley, William |4 aut | |
| 700 | 1 | |a Strydom, Andre |4 aut | |
| 700 | 1 | |a Okun, Eitan |0 (orcid)0000-0001-8474-1487 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuromolecular medicine |d Springer US, 2002 |g 23(2021), 4 vom: 04. März, Seite 561-571 |w (DE-627)346831865 |w (DE-600)2077809-0 |w (DE-576)518182851 |x 1535-1084 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:4 |g day:04 |g month:03 |g pages:561-571 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12017-021-08651-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 4 |b 04 |c 03 |h 561-571 | ||